Evelo Biosciences, Inc.
Evelo Biosciences, Inc. (EVLO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
evlo · stock forecast · 8 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 8 Wall Street analysts in the past 3 months
Buy
8 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.00
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.00 | ↑ 0.00% |
1-day model range: $0–$0. Peak: $0 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · EVLO · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-10-18 | TD Cowen | Downgrade ↓ | Outperform→Market Perform |
| 2023-07-26 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
| 2023-02-15 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
| 2022-11-16 | Chardan Capital | Downgrade ↓ | Buy→Neutral |
| 2022-09-09 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
| 2022-08-24 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
| 2022-08-15 | Chardan Capital | Maintains | Buy→Buy |
| 2021-11-02 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2021-11-01 | Chardan Capital | Upgrade ↑ | Neutral→Buy |
| 2021-06-23 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Evelo Biosciences, Inc. (EVLO) stock. Of the recent 27 rating actions, 2 were upgrades and 4 were downgrades. 8 analysts currently cover EVLO.
Analyst Recommendation Trends
EVLO analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
Revenue Next Year
$0M
EPS This Year
$-2.26
EPS Next Year
$-2.57
↑ 13.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast EVLO EPS of $-2.26 for the current fiscal year, based on estimates from 1 analysts. The EVLO revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The EVLO stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus EVLO price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The EVLO short-term stock prediction for tomorrow is $0.00 (+0.00%).
Evelo Biosciences, Inc. trades on OTC under the ticker EVLO. The EVLO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 63% of covering analysts.
Frequently asked questions
EVLO forecast · 8 questionsAccording to 8 Wall Street analysts, the average 12-month EVLO price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.